MedTrace Logo

The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease

NCT00696215 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-06-12

No results posted yet for this study

Summary

The objective of the study is to assess the effects of rasagiline on cognitive functions in patient with Parkinson's disease. Patients on any dopaminergic medications will be assigned to receive rasagiline 1 mg or placebo over 3 months. Cognitive functions will be assessed by selected neuropsychological tests representing each cognitive domain.

Conditions

Interventions

DRUG

placebo

Placebo 1 mg once a day

DRUG

rasagiline

1mg

Sponsors & Collaborators

  • Istanbul University

    lead OTHER

Principal Investigators

  • MURAT EMRE, PROF · ISTANBUL FACULTY OF MEDICINE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-06-30
Completion
2008-10-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00696215 on ClinicalTrials.gov